Liebel-Flarsheim's Raleigh, NC sterile drug plant failed to investigate microbial and endotoxin test failures and let cleanrooms and equipment fall into disrepair.
What happened
FDA inspected the Liebel-Flarsheim Company LLC drug plant in Raleigh, NC, from March 25 to April 8, 2025. Investigators found at least 40 in-process microbial (bioburden) results above the firm's own action limits since 2022, including 'too numerous to count' results, that were closed out as 'root cause undetermined,' and out-of-specification endotoxin results (endotoxin is a bacterial residue that can cause fever and illness) that the firm invalidated after retesting and then released for U.S. distribution. They also found cleanrooms patched with excessive caulking and tape around HEPA filters and vents, rust on equipment, and a (b)(4) system used to clean filling lines that was corroded and leaking, with liquid pooling and collecting in a bucket, while environmental monitoring had shown excessive microbial contamination since 2019.
What FDA found
The firm did not properly investigate at least 40 in-process microbial results above its own limits since 2022, often concluding 'root cause undetermined' or blaming personnel or environment without evidence.
21 CFR 211.192The firm invalidated multiple out-of-specification endotoxin results after retesting and released those batches for U.S. distribution without an adequate root cause investigation.
21 CFR 211.192Cleanrooms, including the ISO 5 filling line and ISO 7 weigh and formulation rooms, were poorly designed and maintained, with excessive caulking and tape around ceiling HEPA filters and vents and rust on equipment.
21 CFR 211.42(c) and 21 CFR 211.63The (b)(4) system used to clean filling equipment and as a component of the firm's drug products was corroded, with peeling insulation and leaks, allowing filth and microorganisms to spread through manufacturing areas.
21 CFR 211.42(c) and 21 CFR 211.63The firm's corrective actions were inadequate and too slow, with cleanroom reconstruction set for August 2026 and system replacement for April 2027, and no interim measures described.
21 CFR 211.192
What FDA wants
FDA tells the firm to respond in writing within 15 working days with completed corrective actions and detailed plans, including an independent retrospective review of all invalidated out-of-specification results, risk assessments of product already in U.S. distribution (with customer notification or recall if needed), and remediation plans for the facility and the (b)(4) system. FDA also recommends engaging a qualified CGMP (current good manufacturing practice, the FDA rules for how drugs must be made) consultant.
Who should pay attention
- hospitals, clinics and pharmacies that buy terminally sterilized injectables
- distributors and buyers holding these lots in inventory
- sterile drug manufacturers with similar bioburden and endotoxin investigation practices
This is a summary. Read the original letter on fda.gov.